Phase 3 success: The ADAPT OCULUS trial in ocular MG met its primary endpoint (VYVGART high‑titer vs placebo, p=0.012), was well tolerated, and argenx plans to present broader data and file a ...
Positive phase III top-line results for Valneva SA’s chikungunya virus vaccine candidate, VLA-1553, show the study met its primary endpoint of inducing neutralizing antibody titers, setting it up for ...
An antibody titer test identifies and measures the amount of antibodies in your blood, which indicates the strength of your immune response. Doctors use this test to determine if you’ve had past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results